Posted by Michael Wonder on 24 Sep 2025
New subcutaneous formulation of Opdivo receives positive INESSS recommendation for multiple tumour types
23 September 2025 - Milestone decision recognises the value of SC formulation of Opdivo to help support delivery flexibility
BMS today announced that the Institut national d'excellence en santé et en services sociaux (INESSS) has issued a positive recommendation for the reimbursement of Opdivo SC (nivolumab for subcutaneous injection) in Quebec across Health Canada-authorised solid tumour indications where Opdivo (nivolumab) for intravenous infusion is reimbursed.
